Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

Completed · Phase 3

Conditions studied: Allergic Conjunctivitis

In brief

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

Key facts

Study ID

NCT00244543

Run by

Vistakon Pharmaceuticals

People needed

110

Starts

2005-10-01

Last updated by the study team

2011-09-27

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• history of ocular allergies and a positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months; calculated best-corrected visual acuity of 0.6 logMar or better in each eye; positive bilateral conjunctival allergy challenge reaction

You may not qualify if…

• narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium or diagnosis of dry eye; ocular surgical intervention within 3 months; history of refractive surgery within 6 months; known history of retinal detachment, diabetic retinopathy, or progressive retinal disease; presence of active ocular infection positive history of an ocular herpetic infection; preauricular lymphadenopath; manifest signs or symptoms of clinically active allergic conjunctivitis

Where it is running

• Study site — North Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.